Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer (Q28216633)
Jump to navigation
Jump to search
scientific article (publication date: June 2002)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer |
scientific article (publication date: June 2002) |
Statements
Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer (English)
0 references
1 June 2002
0 references
99
0 references
4
0 references
579-82
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference